Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2019 / N 3

Генетические предикторы течения саркоидоза легких
О.И. Балионис, А.Г. Никитин, А.В. Аверьянов

References

1. Hunninghake GW, Costabel U, Ando M, Baughman R, Cordier JF, du Bois R, Eklund A, Kitaichi M, Lynch J, Rizzato G, Rose C, Selroos O, Semenzato G, Sharma OP. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis, Vasculitis, and Diffuse Lung Disease 1999 Sep;16(2):149-73.
2. Rybicki BA, Major M, Popovich Jr J, Maliarik MJ, Iannuzzi MC. Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. American Journal of Epidemiology 1997 Feb;145(3):234-41.
3. Ianuzzi MC, Rybicki BA, Teirstein AS. Sarcoidosis. The New England Journal of Medicine 2007 Nov;357(21):2153-65.
4. Vizel AA, Vizel IYu, Amirov NB. Epidemiology of sarcoidosis in the Russian Federation. The Bulletin of Contemporary Clinical Medicine 2017;10(5):66-73 (In Russian).
5. Hosoda Y, Yamaguchi M, Hiraga Y. Global epidemiology of sarcoidosis. What story do prevalence and incidence tell us? Clinics in Chest Medicine 1997 Dec;18(4):681-94.
6. Arkema EV, Cozier YC. Epidemiology of sarcoidosis: current findings and future directions. Therapeutic Advances in Chronic Disease 2018 Nov;9(11):227-40.
7. Lill H, Kliiman K, Altraja A. Factors signifying gender differences in clinical presentation of sarcoidosis among Estonian population. The Clinical Respiratory Journal 2016 May;10(3):282-90.
8. Sverrild A, Backer V, Kyvik KO, Kaprio J, Milman N, Svendsen CB, Thomsen SF. Heredity in sarcoidosis: a registry-based twin study. Thorax 2008 Oct;63(10):894-6.
9. Valeyre D, Prasse A, Nunes H, Uzunhan Y, Brillet PY, Müller-Quernheim J. Sarcoidosis. The Lancet 2014 Mar;383(9923):1155-67.
10. Newman LS, Rose CS, Bresnitz EA, Rossman MD, Barnard J, Frederick M, Terrin ML, Weinberger SE, Moller DR, McLennan G, Hunninghake G, DePalo L, Baughman RP, Iannuzzi MC, Judson MA, Knatterud GL, Thompson BW, Teirstein AS, Yeager H Jr, Johns CJ, Rabin DL, Rybicki BA, Cherniack R; ACCESS Research Group. A case-control etiologic study of sarcoidosis: environmental and occupational risk factors. American Journal of Respiratory and Critical Care Medicine 2004 Dec;170(12):1324-30.
11. Prezant DJ, Dhala A, Goldstein A, Janus D, Ortiz F, Aldrich TK, Kelly KJ. The incidence, prevalence and severity of sarcoidosis in New York City firefighters. Chest 1999 Nov;116(5):1183-93.
12. Rybicki BA, Iannuzzi MC, Frederick MM, Thompson BW, Rossman MD, Bresnitz EA, Terrin ML, Moller DR, Barnard J, Baughman RP, DePalo L, Hunninghake G, Johns C, Judson MA, Knatterud GL, McLennan G, Newman LS, Rabin DL, Rose C, Teirstein AS, Weinberger SE, Yeager H, Cherniack R; ACCESS Research Group. Familial aggregation of sarcoidosis. A case-control etiologic study of sarcoidosis (ACCESS). American Journal of Respiratory and Critical Care Medicine 2001 Dec;164(11):2085-91.
13. Rybicki BA, Kirkey KL, Major M, Maliarik MJ, Popovich J Jr, Chase GA, Iannuzzi MC. Familial risk ratio of sarcoidosis in African-American sibs and parents. American Journal of Epidemiology 2001 Jan;153(2):188-93.
14. Martenstein H. Knochenveränderungen bei lupus pernio. Zeitschrift für Haut- und Geschlechtskrankheiten 1923;7:308.
15. Brennan NJ, Crean P, Long JP, Fitzgerald MX. High prevalence of familial sarcoidosis in an Irish population. Thorax 1984 Jan;39(1):14-8.
16. Harrington D, Major M, Rybicki B, Popovich J Jr, Maliarik M, Iannuzzi MC. Familial analysis of 91 families. Sarcoidosis 1994;11:240-3.
17. Baughman RP, Judson MA. Relapses of sarcoidosis: what are they and can we predict who will get them? The European Respiratory Journal 2014 Feb;43(2):337-9.
18. Chuchalin AG, Avdeyev SN, Aysanov ZR, Baranova OP, Borisov SE, Vizel AA, Vizel IYu, Zaytsev AA, Ivanova DA, Ilkovich MM, Lovacheva OV, Ovsyannikov NV, Petrov DV, Romanov VV, Samsonova MV, Sivokozov IV, Solovyova IP, Stepanyan IE, Tyurin IE, Chernyaev AL, Shmelev EI, Shmeleva NM. Russian Respiratory Society. Federal clinical guidelines for the diagnosis and treatment of sarcoidosis. Moscow, 2016: 30-2 (In Russian).
19. Panselinas E, Judson MA. Acute pulmonary exacerbations of sarcoidosis. Chest 2012 Oct;142(4):827-36.
20. Panselinas E, Judson MA. Acute pulmonary exacerbation of sarcoidosis. In: Pulmonary sarcoidosis: a guide for the practicing clinician. Judson MA, editor. New York, NY: Springer; 2014: 65-76.
21. Baughman RP, Judson MA, Teirstein A, Yeager H, Rossman M, Knatterud GL, Thompson B. Presenting characteristics as predictors of duration of treatment in sarcoidosis. QJM 2006 May;99(5):307-15.
22. Baughman RP, Nagai S, Balter M, Costabel U, Drent M, du Bois R, Grutters JC, Judson MA, Lambiri I, Lower EE, Muller-Quernheim J, Prasse A, Rizzato G, Rottoli P, Spagnolo P, Teirstein A. Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force. Sarcoidosis, Vasculitis, and Diffuse Lung Disease 2011 Jul;28(1):56-64.
23. Dwyer-Lindgren L, Bertozzi-Villa A, Stubbs RW, Morozoff C, Shirude S, Naghavi M, Mokdad AH, Murray CJL. Trends and patterns of differences in chronic respiratory disease mortality among US counties, 1980-2014. JAMA 2017 Sep;318(12):1136-49.
24. Mirsaeidi M, Machado RF, Schraufnagel D, Sweiss NJ, Baughman RP. Racial difference in sarcoidosis mortality in the United States. Chest 2015 Feb;147(2):438-49.
25. Jamilloux Y, Maucort-Boulch D, Kerever S, Gerfaud-Valentin M, Broussolle C, Eb M, Valeyre D, Seve P. Sarcoidosis-related mortality in France: a multiple-cause-of-death analysis. The European Respiratory Journal 2016 Dec;48(6):1700-9.
26. Nowiński A, Puścińska E, Goljan A, Peradzynska J, Bednarek M, Korzybski D, Kamiński D, Stokłosa A, Czystowska M, Śliwiński P, Górecka D. The influence of comorbidities on mortality in sarcoidosis: a observational prospective cohort study. The Clinical Respiratory Journal 2017 Sep;11(5):648-56.
27. Baughman RP, Ploysongsang Y, Roberts RD, Srivastava L. Effects of sarcoid and steroids on angiotensin-converting enzyme. The American Review of Respiratory Disease 1983 Oct;128(4):631-3.
28. Kohn H, Klech H, Mostbeck A, Kummer F. 67 Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood T-lymphocytes. European Journal of Nuclear Medicine 1982;7(9):413-6.
29. Keir G, Wells AU. Assessing pulmonary disease and response to therapy: which test? Seminars in Respiratory and Critical Care Medicine 2010 Aug;31(4):409-18.
30. Ma X, Dai H, Wang C. Clinical features and prognosis of Chinese sarcoidosis patients. The European Respiratory Journal 2018;52(Suppl 62):PA3012.
31. Gottlieb JE, Israel HL, Steiner RM, Triolo J, Patrick H. Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy. Chest 1997 Mar;111(3):623-31.
32. Rodrigues SC, Rocha NA, Lima MS, Arakaki JS, Coletta EN, Ferreira RG, Gonzaga LR, Pereira CA. Factor analysis of sarcoidosis phenotypes at two referral centers in Brazil. Sarcoidosis, Vasculitis, and Diffuse Lung Disease 2011 Jul;28(1):34-43
33. Panselinas E, Rodgers JK, Judson MA. Clinical outcomes in sarcoidosis after cessation of infliximab treatment. Respirology (Carlton, Vic.) 2009 May;14(4):522-8.
34. Baughman RP, Lower EE, Ingledue R, Kaufman AH. Management of ocular sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Disease 2012 Mar;29(1):26-33.
35. Vorselaars ADM, Verwoerd A, van Moorsel CH, Keijsers RG, Rijkers GT, Grutters JC. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis. The European Respiratory Journal 2014 Feb;43(2):602-9.
36. Vizel IYu. Sarcoidosis in the Republic of Tatarstan: efficacy of diagnosis and treatment, analysis of long-term results [Dissertation for the Degree of the Doctor of Medical Sciences]. Kazan 2017. 370 p. (In Russian).
37. Iannuzzi MC, Fontana JR. Sarcoidosis: clinical presentation, immunopathogenesis, and therapeutics. JAMA 2011Jan;305(4):391-9.
38. Fischer A, Nothnagel M, Schürmann M, Müller-Quernheim J, Schreiber S, Hofmann S. A genome-wide linkage analysis in 181 German sarcoidosis families using clustered biallelic markers. Chest 2010 Jul;138(1):151-7.
39. Schürmann M, Reichel P, Müller-Myhsok B, Schlaak M, Müller-Quernheim J, Schwinger E. Results from a genome-wide search for predisposing genes in sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2001 Sep;164(5):840-6.
40. Brewerton DA, Cockburn C, James DC, James DG, Neville E. HLA antigens in sarcoidosis. Clinical & Experimental Immunology 1977 Feb;27(2):227-9.
41. Hedfors E, Lindström F. HLA-B8/DR3 in sarcoidosis: correlation to acute onset disease with arthritis. Tissue Antigens 1983 Sep;22(3):200-3.
42. Smith MJ, Turton CW, Mitchell DN, Turner-Warwick M, Morris LM, Lawler SD. Association of HLA B8 with spontaneous resolution in sarcoidosis. Thorax 1981 Apr;36(4):296-8.
43. Lio D, Candore G, Romano GC, D’Anna C, Gervasi F, Di Lorenzo G, Modica MA, Potestio M, Caruso C. Modification of cytokine patterns in subjects bearing the HLA-B8, DR3 phenotype: implications for autoimmunity. Cytokines, Cellular & Molecular Therapy 1997 Dec;3(4):217-24.
44. Spagnolo P, Sato H, Grutters JC, Renzoni EA, Marshall SE, Ruven HJ, Wells AU, Tzouvelekis A, van Moorsel CH, van den Bosch JM, du Bois RM, Welsh KI. Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens 2007 Sep;70(3):219-27.
45. Spagnolo P, Sato H, Grunewald J, Brynedal B, Hillert J, Mañá J, Wells AU, Eklund A, Welsh KI, du Bois RM. A common haplotype of the C-C chemokine receptor 2 gene and HLA-DRB1*0301 are independent genetic risk factors for Löfgren’s syndrome. Journal of Internal Medicine 2008 Nov;264(5):433-41.
46. Grunewald J, Brynedal B, Darlington P, Nisell M, Cederlund K, Hillert J, Eklund A. Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients. Respiratory Research 2010 Feb;11:25.
47. Sato H, Woodhead FA, Ahmad T, Grutters JC, Spagnolo P, van den Bosch JM, Maier LA, Newman LS, Nagai S, Izumi T, Wells AU, du Bois RM, Welsh KI. Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups. Human Molecular Genetics 2010 Oct;19(20):4100-11.
48. Wennerstrom A, Pietinalho A, Vauhkonen H, Lahtela L, Palikhe A, Hedman J, Purokivi M, Varkki E, Seppänen M, Lokki ML, Selroos O; Finnish Sarcoidosis Study Group. HLA-DRB1 allele frequencies and C4 copy number variation in Finnish sarcoidosis patients and associations with disease prognosis. Human Immunology 2012 Jan;73(1):93-100.
49. Rossman MD, Thompson B, Frederick M, Maliarik M, Iannuzzi MC, Rybicki BA, Pandey JP, Newman LS, Magira E, Beznik-Cizman B,Monos D; ACCESS Group. HLA-DRB1*1101: a significant risk factor for sarcoidosis in blacks and whites. American Journal of Human Genetics 2003 Oct;73(4):720-35.
50. Grunewald J, Idali F, Kockum I, Seddighzadeh M, Nisell M, Eklund A, Padyukov L. Major histocompatibility complex class II transactivator gene polymorphism: associations with Löfgren’s syndrome. Tissue Antigens 2010 Aug;76(2):96-101.
51. Iannuzzi MC, Maliarik MJ, Poisson LM, Rybicki BA. Sarcoidosis susceptibility and resistance HLA-DQB1 alleles in African Americans. American Journal of Respiratory and Critical Care Medicine 2003 May;167(9):1225-31.
52. Grunewald J, Eklund A, Olerup O. Human leukocyte antigen class I alleles and the disease course in sarcoidosis patients. American Journal of Respiratory and Critical Care Medicine 2004Mar;169(6):696-702.
53. Zachary AA, Bias WB, Johnson A, Rose SM, Leffell MS. Antigen, allele, and haplotype frequencies report of the ASHI minority antigens workshops: part 1, African-Americans. Human Immunology 2001 Oct;62(10):1127-36.
54. Rybicki BA, Levin AM, McKeigue P, Datta I, Gray-McGuire C, Colombo M, Reich D, Burke RR, Iannuzzi MC. A genome-wide admixture scan for ancestry-linked genes predisposing to sarcoidosis in African-Americans. Genes & Immunity 2011 Mar;12(2):67-77.
55. Sato H, Grutters JC, Pantelidis P, Mizzon AN, Ahmad T, Van Houte AJ, Lammers JW, Van Den Bosch JM, Welsh KI, Du Bois RM. HLA-DQB1*0201: a marker for good prognosis in British and Dutch patients with sarcoidosis. American Journal of Respiratory Cell and Molecular Biology 2002 Oct;27(4):406-12.
56. Van den Berg-Loonen EM, Voorter CEM, Drent M. Strong association of severe pulmonary sarcoidosis with HLA-DQB1*0602. Human Immunology 2004 Sep;65(9):826-35.
57. Levin AM, Adrianto I, Datta I, Iannuzzi MC, Trudeau S, Li J, Drake WP, Montgomery CG, Rybicki BA. Association of HLA-DRB1 with sarcoidosis susceptibility and progression in African Americans. American Journal of Respiratory Cell and Molecular Biology 2014 Aug;53(2):206-16.
58. Fingerlin TE, Hamzeh E, Maier LA. Genetics of sarcoidosis. Clinics in Chest Medicine 2015 Dec;36(4):569-84.
59. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. American Journal of Respiratory and Critical Care Medicine 1999 Aug;160(2):736-55.
60. Sharma P, Smith I, Maguire G, Stewart S, Shneerson J, Brown MJ. Clinical value of ACE genotyping in diagnosis of sarcoidosis. The Lancet 1997 May;349(9065):1602-3.
61. Maliarik MJ, Rybicki BA, Malvitz E, Sheffer RG, Major M, Popovich J Jr, Iannuzzi MC. Angiotensin-converting enzyme gene polymorphism and risk of sarcoidosis. American Journal of Respiratory and Critical Care Medicine 1998 Nov;158(5 Pt 1):1566-70.
62. Rybicki BA, Maliarik MJ, Poisson LM, Iannuzzi MC. Sarcoidosis and granuloma genes: a family-based study in African-Americans. The European Respiratory Journal 2004 Sep;24(2):251-7.
63. Planck A, Eklund A, Yamaguchi E, Grunewald J. Angiotensin-converting enzyme gene polymorphism in relation to HLA-DR in sarcoidosis. Journal of Internal Medicine 2002 Mar;251(3):217-22.
64. Schürmann M, Reichel P, Müller-Myhsok B, Dieringer T, Wurm K, Schlaak M, Müller-Quernheim J, Schwinger E. Angiotensin-converting enzyme (ACE) gene polymorphisms and familial occurrence of sarcoidosis. Journal of Internal Medicine 2001 Jan;249(1):77-83.
65. Kruit A, Ruven HJT, Grutters JC, van den Bosch JM. Angiotensin II receptor type 1 1166 A/C and angiotensin converting enzyme I/D gene polymorphisms in a Dutch sarcoidosis cohort. Sarcoidosis, Vasculitis, and Diffuse Lung Disease 2010 Jul;27(2):147-52.
66. Biller H, Ruprecht B, Gaede KI, Müller-Quernheim J, Zissel G. Gene polymorphisms of ACE and the angiotensin receptor AT2R1 influence serum ACE levels in sarcoidosis. Sarcoidosis, Vasculitis, and Diffuse Lung Disease 2009 Jul;26(2):139-46.
67. Takemoto Y, Sakatani M, Takami S, Tachibana T, Higaki J, Ogihara T, Miki T, Katsuya T, Tsuchiyama T, Yoshida A, Yu H, Tanio Y, Ueda E. Association between angiotensin II receptor gene polymorphism and serum angiotensin converting enzyme (SACE) activity in patients with sarcoidosis. Thorax 1998 Jun;53(6):459-62.
68. West AP, Koblansky AA, Ghosh S. Recognition and signaling by toll-like receptors. Annual Review of Cell and Developmental Biology 2006;22:409-37.
69. Pabst S, Baumgarten G, Stremmel A, Lennarz M, Knüfermann P, Gillissen A, Vetter H, Grohé C. Toll-like receptor (TLR) 4 polymorphisms are associated with a chronic course of sarcoidosis. Clinical & Experimental Immunology 2006 Mar;143(3):420-6.
70. Valentonyte R, Hampe J, Huse K, Rosenstiel P, Albrecht M, Stenzel A, Nagy M, Gaede KI, Franke A, Haesler R, Koch A, Lengauer T, Seegert D, Reiling N, Ehlers S, Schwinger E, Platzer M, Krawczak M, Müller-Quernheim J, Schürmann M, Schreiber S. Sarcoidosis is associated with a truncating splice site mutation in BTNL2. Nature Genetics 2005 Apr;37(4):357-64.
71. Dai S, Murphy GA, Crawford F, Mack DG, Falta MT, Marrack F, Kappler JW, Fontenot AP. Crystal structure of HLA-DP2 and implications for chronic beryllium disease. Proceedings of the National Academy of Sciences of the USA 2010 Apr;107(16):7425-30.
72. McDougal KE, Fallin MD, Moller DR, Song Z, Cutler DJ, Steiner LL, Cutting GR; ACCESS Research Group. Variation in the lymphotoxin-alpha/tumor necrosis factor locus modifies risk of erythema nodosum in sarcoidosis. The Journal of Investigative Dermatology 2009 Aug;129(8):1921-6.
73. Mrazek F, Holla LI, Hutyrova B, Znojil V, Vasku A, Kolek V, Welsh KI, Vacha J, du Bois RM, Petrek M. Association of tumour necrosis factor-alpha, lymphotoxin-alpha and HLA-DRB1 gene polymorphisms with Löfgren’s syndrome in Czech patients with sarcoidosis. Tissue Antigens 2005 Feb;65(2):163-71.
74. Wijnen PA, Nelemans PJ, Verschakelen JA, Bekers O, Voorter CE, Drent M. The role of tumor necrosis factor alpha G-308A polymorphisms in the course of pulmonary sarcoidosis. Tissue Antigens 2010 Mar;75(3):262-8.
75. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNF-alpha release from alveolar macrophages and serum level of sIL-2R are prognostic markers. American Journal of Respiratory and Critical Care Medicine 1997 Nov;156(5):1586-92.
76. Grutters JC, Sato H, Pantelidis P, Lagan AL, McGrath DS, Lammers JWJ, van den Bosch JMM, Wells AU, du Bois RM, Welsh KI. Increased frequency of the uncommon tumor necrosis factor-857T allele in British and Dutch patients with sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2002 Apr;165(8):1119-24.
77. Seitzer U, Swider C, Stüber F, Suchnicki K, Lange A, Richter E, Zabel P, Müller-Quernheim J, Flad HD, Gerdes J. Tumour necrosis factor alpha promoter gene polymorphism in sarcoidosis. Cytokine 1997 Oct;9(10):787-90.
78. Swider C, Schnittger L, Bogunia-Kubik K, Gerdes J, Flad H, Lange A, Seitzer U. TNF-alpha and HLA-DR genotyping as potential prognostic markers in pulmonary sarcoidosis. European Cytokine Network 1999 Jun;10(2):143-6.
79. Labunski S, Posern G, Ludwig S, Kundt G, Bröcker EB, Kunz M. Tumour necrosis factor-alpha promoter polymorphism in erythema nodosum. Acta Dermato-Venereologica 2001 Jan-Feb;81:18-21.
80. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. The New England Journal of Medicine 1994 Nov;331(19):1286-92.
81. Moses HL, Yang EY, Pietenpol JA. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 1990 Oct;63(2):245-7.
82. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD. Genetic control of the circulating concentration of transforming growth factor type beta1. Human Molecular Genetics 1999 Jan;8(1):93-7.
83. Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A, Ikeda K. Association of a polymorphism of the transforming growth factorbeta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. Journal of Bone and Mineral Research 1998 Oct;13(10):1569-76.
84. Salez F, Gosset P, Copin MC, Lamblin Degros C, Tonnel AB, Wallaert B. Transforming growth factor-beta1 in sarcoidosis. The European Respiratory Journal 1998 Oct;12(4):913-9.
85. Kruit A, Grutters JC, Ruven HJT, van Moorsel CH, Weiskirchen R, Mengsteab S, van den Bosch JM. Transforming growth factor-β gene polymorphisms in sarcoidosis patients with and without fibrosis. Chest 2006 Jun;129(6):1584-91.
86. Jonth AC, Silveira L, Fingerlin TE, Sato H, Luby JC, Welsh KI, Rose CS, Newman LS, du Bois RM, Maier LA; ACCESS Group. TGF-beta1 variants in chronic beryllium disease and sarcoidosis. Journal of Immunology (Baltimore, Md.: 1950) 2007 Sep;179(6):4255-62.
87. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: an effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006 Jun;24(6):677-88.
88. Hoeve MA, Savage ND, de Boer T, Langenberg DM, de Waal Malefyt R, Ottenhoff TH, Verreck FA. Divergent effects of IL-12 and IL-23 on the production f IL-17 by human T cells. European Journal of Immunology 2006 Mar;36(3):661-70.
89. Fischer A, Nothnagel M, Franke A, Jacobs G, Saadati HR, Gaede KI, Rosenstiel P, Schürmann M, Müller-Quernheim J, Schreiber S, Hofmann S. Association of inflammatory bowel disease risk loci with sarcoidosis, and its acute and chronic subphenotypes. The European Respiratory Journal 2011 Mar;37(3):610-6.
90. Fischer A, Ellinghaus D, Nutsua M, Hofmann S, Montgomery CG, Iannuzzi MC, Rybicki BA, Petrek M, Mrazek F, Pabst S, Grohé C, Grunewald J, Ronninger M, Eklund A, Padyukov L, Mihailovic-Vucinic V, Jovanovic D, Sterclova M, Homolka J, Nöthen MM, Herms S, Gieger C, Strauch K, Winkelmann J, Boehm BO, Brand S, Büning C, Schürmann M, Ellinghaus E, Baurecht H, Lieb W, Nebel A, Müller-Quernheim J, Franke A, Schreiber S; GenPhenReSa Consortium. Identification of immune-relevant factors conferring sarcoidosis genetic risk. American Journal of Respiratory and Critical Care Medicine 2015 Sep;192(6):727-36.
91. Hofmann S, Franke A, Fischer A, Jacobs G, Nothnagel M, Gaede KI, Schürmann M, Müller-Quernheim J, Krawczak M, Rosenstiel P, Schreiber S. Genome-wide association study identifies ANXA11 as a new susceptibility locus for sarcoidosis. Nature Genetics 2008 Sep;40(9):1103-6.
92. Mrazek F, Stahelova A, Kriegova E, Fillerova R, Zurkova M, Kolek V, Petrek M. Functional variant ANXA11 R230C: true marker of protection and candidate disease modifier in sarcoidosis. Genes & Immunity 2011 Sep;12(6):490-4.
93. Petrek M, Drábek J, Kolek V, Zlámal J, Welsh KI, Bunce M, Weigl E, Du Bois R. CC chemokine receptor gene polymorphisms in Czech patients with pulmonary sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2000 Sep;162(3 Pt 1):1000-3.
94. Spagnolo P, Renzoni EA, Wells AU, Sato H, Grutters JC, Sestini P, Abdallah A, Gramiccioni E, Ruven HJ, du Bois RM, Welsh KI. C-C chemokine receptor 2 and sarcoidosis: association with Lofgren’s syndrome. American Journal of Respiratory and Critical Care Medicine 2003 Nov;168(10):1162-6.
95. Samson M, Soularue P, Vassart G, Parmentier M. The genes encoding the human CC-chemokine receptors CC-CKR1 to CC-CKR5 (CMKBR1-CMKBR5) are clustered in the p21.3-p24 region of chromosome 3. Genomics 1996 Sep;36(3):522-6.
96. Blanpain C, Migeotte I, Lee B, Vakili J, Doranz BJ, Govaerts C, Vassart G, Doms RW, Parmentier M. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999 Sep;94(6):1899-905.
97. Baggiolini M, Loetscher P. Chemokines in inflammation and immunity. Immunology Today 2000 Sep;21(9):418-20.
98. Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Müller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. Journal of Investigative Medicine 1998 Jun;46(5):223-31.
99. Capelli A, Di Stefano A, Lusuardi M, Gnemmi I, Donner CF. Increased macrophage inflammatory protein-1 alpha and macrophage inflammatory protein-1 beta levels in bronchoalveolar lavage fluid of patients affected by different stages of pulmonary sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2002 Jan;165(2):236-41.
100. Katchar K, Eklund A, Grunewald J. Expression of Th1 markers by lung accumulated T cells in pulmonary sarcoidosis. Journal of Internal Medicine 2003 Nov;254(6):564-71.
101. Iida K, Kadota J, Kawakami K, Matsubara Y, Shirai R, Kohno S. Analysis of T cell subsets and beta chemokines in patients with pulmonary sarcoidosis. Thorax 1997 May;52(5):431-7.
102. Keane MP, Standiford TJ, Strieter RM. Chemokines are important cytokines in the pathogenesis of interstitial lung disease. The European Respiratory Journal 1997 Jun;10(6):1199-202.
103. Petrek M, Pantelidis P, Southcott AM, Lympany P, Safranek P, Black CM, Kolek V, Weigl E, du Bois RM. The source and role of RANTES in interstitial lung disease. The European Respiratory Journal 1997;10(6):1207-16.
104. Fischer A, Valentonyte R, Nebel A, Nothnagel M, Müller-Quernheim J, Schürmann M, Schreiber S. Female-specific association of C-C chemokine receptor 5 gene polymorphisms with Löfgren’s syndrome. Journal of Molecular Medicine (Berlin, Germany) 2008 May;86(5):553-61.
105. Spagnolo P, Renzoni EA, Wells AU, Copley SJ, Desai SR, Sato H, Grutters JC, Abdallah A, Taegtmeyer A, du Bois RM, Welsh KI. C-C chemokine receptor 5 gene variants in relation to lung disease in sarcoidosis. American Journal of Respiratory and Critical Care Medicine 2005 Sep;172(6):721-8.
106. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Cézard JP, Belaiche J, Almer S, Tysk C, O’Morain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 2001 May;411(6837):599-603.
107. Sato H, Williams HRT, Spagnolo P, Abdallah A, Ahmad T, Orchard TR, Copley SJ, Desai SR, Wells AU, du Bois RM, Welsh KI. CARD15/NOD2 polymorphisms are associated with severe pulmonary sarcoidosis. The European Respiratory Journal 2010 Feb;35(2):324-30.
108. Hofmann S, Fischer A, Nothnagel M, Jacobs G, Schmid B, Wittig M, Franke A, Gaede KI, Schürmann M, Petrek M, Mrazek F, Pabst S, Grohé C, Grunewald J, Ronninger M, Eklund A, Rosenstiel P, Höhne K, Zissel G, Müller-Quernheim J, Schreiber S. Genome-wide association analysis reveals 12q13.3-q14.1 as new risk locus for sarcoidosis. The European Respiratory Journal 2013 Apr;41(4):888-900.
109. Hsu DR, Economides AN, Wang X, Eimon PM, Harland RM. The Xenopus dorsalizing factor Gremlin identifies a novel family of secreted proteins that antagonize BMP activities. Molecular cell 1998 Apr;1(5):673-83.
110. Heron M, van Moorsel CH, Grutters JC, Huizinga TW, van der Helm-van Mil AH, Nagtegaal MM, Ruven HJ, van den Bosch JM. Genetic variation in GREM1 is a risk factor for fibrosis in pulmonary sarcoidosis. Tissue Antigens 2010 Feb;77(2):112-7.
111. Lopez-Campos JL, Rodriguez-Rodriguez D, Rodriguez-Becerra E, Michavila IA, Guerra JF, Hernandez FJ, Casanovae A, Gamero FC, Romero Ortiz A, Arellano-Orden E, Montes-Worboys A. Association of the 3050G>C polymorphism in the cyclooxygenase 2 gene with systemic sarcoidosis. Archives of Medical Research 2008 Jul;39(5):525-30.
112. Loegering DJ, Blumenstock FA. Depressing hepatic macrophage complement receptor function causes increased susceptibility to endotoxemia and infection. Infection and Immunity 1985 Mar;47(3):659-64.
113. Cornacoff JB, Hebert LA, Smead WL, Vanaman ME, Birmingham DJ, Waxman FJ. Primate erythrocyte-immune complex clearing mechanism. Journal of Clinical Investigation 1983 Feb;71(2):236-47.
114. Zorzetto M, Bombieri C, Ferrarotti I, Medaglia S, Agostini C, Tinelli C, Malerba G, Carrabino N, Beretta A, Casali L, Pozzi E, Pignatti PF, Semenzato G, Cuccia MC, Luisetti M. Complement receptor 1 gene polymorphisms in sarcoidosis. American Journal of Respiratory Cell and Molecular Biology 2002 Jul;27(3):17-23.
115. Matouschek A. Protein unfolding: an important process in vivo? Current Opinion in Structural Biology 2003 Feb;13(1):98-109.
116. Asea A, Kraeft SK, Kurt-Jones EA, Stevenson MA, Chen LB, Finberg RW, Koo GC, Calderwood SK. HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine. Nature Medicine 2000 Apr;6(4):435-42.
117. Jenkins SC, March RE, Campbell RD, Milner CM. A novel variant of the MHC-linked hsp70, hsp70-hom, is associated with rheumatoid arthritis. Tissue Antigens 2000 Jul;56(1):38-44.
118. Hrycaj P, Wurm K, Mennet P, Müller W. Antibodies to heat shock proteins in patients with pulmonary sarcoidosis. Sarcoidosis 1995 Sep;12(2):124-30.
119. De Smet MD, Ramadan A. Circulating antibodies to inducible heat shock protein 70 in patients with uveitis. Ocular Immunology and Inflammation 2001 Jun;9(2):85-92.
120. Bogunia-Kubik K, Koscinska K, Suchnicki K, Lange A. HSP70-hom gene single nucleotide (+2763 G/A and +2437 C/T) polymorphisms in sarcoidosis. International Journal of Immunogenetics 2006 Apr;33(2):135-40.
121. Ishihara M, Ohno S, Ishida T, Mizuki N, Ando H, Naruse T, Ishihara H, Inoko H. Genetic polymorphisms of the TNFB and HSP70 genes located in the human major histocompatibility complex in sarcoidosis. Tissue Antigens 1995 Jul;46(1):59-62.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]